| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000034129 |
| Receipt No. | R000038909 |
| Scientific Title | Efficacy trial of continuous ingestion of plant derived ingredients. [trial number g2018006] |
| Date of disclosure of the study information | 2018/09/20 |
| Last modified on | 2019/08/21 (Ver. 5) |
| Basic information | ||
| Public title | Efficacy trial of continuous ingestion of plant derived ingredients. [trial number g2018006] | |
| Acronym | Efficacy of plant derived ingredients. [trial number g2018006] | |
| Scientific Title | Efficacy trial of continuous ingestion of plant derived ingredients. [trial number g2018006] | |
| Scientific Title:Acronym | Efficacy of plant derived ingredients. [trial number g2018006] | |
| Region |
|
|
| Condition | |||
| Condition | Healthy adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To investigate effects of continuous ingestion of plant derived ingredients for 4 weeks on glucose metabolism in healthy adults with high normaland impaired fasting glucose |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Blood glucose |
| Key secondary outcomes | Insulin, glucagon, 1.5-AG, glycol-albumin, gastrointestinal hormone, triglyceride, free fatty acids, apo B48, ketone body, body weight, body fat ratio, appetite (questionnaire) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | YES |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Control food A, once daily,
continuous ingestion for 4 weeks |
|
| Interventions/Control_2 | Test food B, once daily,
continuous ingestion for 4 weeks |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | (1) Healthy male adults aged 20 and older, under 65
(2) Subjects with fasting glucose ranged 100 mg/dL and more, less than126 mg/dL (3) Subjects can consume test foods, and record life diaries and meal diaries (4) Subjects who have given written informed consent prior to study |
|||
| Key exclusion criteria | (1)Subjects diagnosed with diabetes, or taking drugs related diabetes
(2)Subjects who have history or symptom of cardiovascular disease or cerebrovascular disease (3)Subjects who have symptom of liver, kidney or respiratory disease, endocrine disorder, metabolic disorder, organ disorder, gout, rheumatism, autoimmune disease, allergy disease, mental disorder, cancer, infection disease, or other diseases (4)Subjects who have a history of resection of gastrointestinal tract, excluding cecal resection surgery (5)Heavy drinker (over 30g alcohol per day) (6)Subjects who have donated over 200 mL of blood within the last one month prior to the current study or over 400 mL of blood within the last three months prior to the study (7)Subjects who have severe anemia (Hb <=7g/dL) (8)Subjects who have food allergies for test foods (9)Subjects who plan to participate in other clinical study during the current study (10)Subjects who are judged to be inappropriate for the study by the medical doctor or investigator for other reasons |
|||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kao Corporation | ||||||
| Division name | Biological Science Research laboratories | ||||||
| Zip code | 131-8501 | ||||||
| Address | 2-1-3, Bunka, Sumida-ku, Tokyo, 131-8501, Japan | ||||||
| TEL | 03-5630-7266 | ||||||
| hibi.masanobu@kao.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kao Corporation | ||||||
| Division name | Biological Science Research laboratories | ||||||
| Zip code | 131-8501 | ||||||
| Address | 2-1-3, Bunka, Sumida-ku, Tokyo, 131-8501, Japan | ||||||
| TEL | 03-5630-7266 | ||||||
| Homepage URL | |||||||
| hibi.masanobu@kao.com | |||||||
| Sponsor | |
| Institute | Clinical Support Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kao Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Medical corporation Hokubukai Utsukushigaoka Hospital IRB |
| Address | 61-1, Shinei, Kiyota-ku, Sapporo, Hokkaido, 004-0839, Japan |
| Tel | 011-882-0111 |
| wakimoto@ughp-cpc.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団翔嶺館新札幌聖陵ホスピタル(北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | Unpublished due to the protocol including the intellectual property rights |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | works in progress | ||||||
| Number of participants that the trial has enrolled | 30 | ||||||
| Results | No significant difference in the primary outcome |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Healthy adults with high normal and impaired fasting glucose |
||||||
| Participant flow | 30 participants completed |
||||||
| Adverse events | No adverse effect related to the test diets reported |
||||||
| Outcome measures | Glucose |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038909 |